newsfilter
← Latest News
GlobeNewswire·

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

EIKN
  • Eikon Therapeutics announced seven abstracts accepted for presentation at the ESMO Congress 2026 covering clinical updates for EIK1001, EIK1003, EIK1004, and EIK1005.
  • Data presented at ASCO 2026 showed encouraging activity for EIK1001 combined with pembrolizumab and chemotherapy in front-line advanced NSCLC treatment within the TeLuRide-005 Phase 2 trial.
  • Preliminary evidence from ASCO 2026 indicated that the PARP1-selective inhibitor EIK1003 could be safely combined with full-dose paclitaxel for second-line breast and ovarian cancer treatments.
  • The TeLuRide-006 Phase 2/3 registrational trial for EIK1001 in first-line advanced melanoma progressed through a first interim analysis, with the Data Monitoring Committee recommending a single dosing regimen for expansion.
  • Eikon dosed the first patient in July 2026 for the TeLuRide-008 Phase 2/3 trial evaluating EIK1001 with pembrolizumab and chemotherapy for first-line stage 4 NSCLC.
  • Ma. Fatima "Fama" Francisco was appointed to the Board of Directors, bringing over 35 years of global commercial experience from Procter & Gamble.
  • Eikon ended the second quarter of 2026 with $531.2 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into the second half of 2027.
  • Research and development expenses for the quarter were $75.5 million, an increase of 9% year-over-year due to advanced clinical trial activity.
  • General and administrative expenses decreased 56% to $17.9 million, primarily driven by a lack of impairment charges compared to the prior year period.
  • Net loss for the second quarter of 2026 was $88.4 million, a reduction from $105.2 million in the same period of 2025.
  • EIK1006, a next-generation androgen receptor antagonist, is expected to have an IND submission by the end of 2026.
  • Upcoming data presentations scheduled for October 2026 at ESMO include results for EIK1001, EIK1003, EIK1004, and EIK1005.